These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463 [TBL] [Abstract][Full Text] [Related]
26. Low-dose enalapril reduces angiotensin II and attenuates diabetic-induced cardiac and autonomic dysfunctions. Malfitano C; De Angelis K; Fernandes T; Wichi RB; Rosa K; Pazzine M; Mostarda C; Ronchi FA; Oliveira EM; Casarini DE; Irigoyen MC J Cardiovasc Pharmacol; 2012 Jan; 59(1):58-65. PubMed ID: 21921804 [TBL] [Abstract][Full Text] [Related]
27. First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226 [TBL] [Abstract][Full Text] [Related]
28. Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. Petrie CJ; Ponikowski P; Metra M; Mitrovic V; Ruda M; Fernandez A; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Voors AA Clin Exp Hypertens; 2018; 40(7):637-643. PubMed ID: 29265934 [TBL] [Abstract][Full Text] [Related]
29. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012. von Haehling S Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525 [TBL] [Abstract][Full Text] [Related]
30. Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Coulson CC; Thorp JM; Mayer DC; Cefalo RC Obstet Gynecol; 1996 Apr; 87(4):610-2. PubMed ID: 8602317 [TBL] [Abstract][Full Text] [Related]
31. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). Marshall SA; O'Sullivan K; Ng HH; Bathgate RAD; Parry LJ; Hossain MA; Leo CH Eur J Pharmacol; 2017 Jul; 807():190-197. PubMed ID: 28478069 [TBL] [Abstract][Full Text] [Related]
32. Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis. Bennett RG; Simpson RL; Hamel FG World J Gastroenterol; 2017 Jun; 23(22):3999-4006. PubMed ID: 28652653 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary arterial compliance and pulmonary hemodynamic effects of Serelaxin in a sheep model. Schiffner R; Reiche J; Schmidt M; Jung C; Walther S; Irintchev A; Bischoff SJ Clin Hemorheol Microcirc; 2017; 66(3):219-229. PubMed ID: 28482627 [TBL] [Abstract][Full Text] [Related]
34. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure? Dschietzig TB Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696 [TBL] [Abstract][Full Text] [Related]
35. Systemic and renal effects of enalapril and its effects on cardiac mass. Dunn FG; Oigman W; Ventura HO; Messerli FH; Kobrin I; Frohlich ED J Hypertens Suppl; 1984 Dec; 2(2):S57-61. PubMed ID: 6100878 [TBL] [Abstract][Full Text] [Related]
36. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K J Card Fail; 2009 Apr; 15(3):182-90. PubMed ID: 19327619 [TBL] [Abstract][Full Text] [Related]
37. A role for glucagon in cardiac therapy. Parmley WW; Sonnenblick EH Am J Med Sci; 1969 Oct; 258(4):224-9. PubMed ID: 4309903 [No Abstract] [Full Text] [Related]
38. Human recombinant relaxin reduces heart injury and improves ventricular performance in a swine model of acute myocardial infarction. Perna AM; Masini E; Nistri S; Bani Sacchi T; Bigazzi M; Bani D Ann N Y Acad Sci; 2005 May; 1041():431-3. PubMed ID: 15956741 [TBL] [Abstract][Full Text] [Related]
39. Antifibrotic Actions of Serelaxin - New Roles for an Old Player. Samuel CS; Summers RJ; Hewitson TD Trends Pharmacol Sci; 2016 Jun; 37(6):485-497. PubMed ID: 26996448 [TBL] [Abstract][Full Text] [Related]
40. Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease. Royce SG; Lim CX; Patel KP; Wang B; Samuel CS; Tang ML Clin Exp Allergy; 2014 Nov; 44(11):1399-408. PubMed ID: 25113628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]